Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 79.53% is in line with its 5-year average of 81.72%, around the middle of its 5-year range (73.80%–89.30%).
As of the fiscal period ended Tuesday, June 30, 2026. 0.08% below its 12-month average of 79.59%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 79.54%.
GROSS MARGIN
79.53%
GROSS MARGIN AVG TTM
79.59%
GROSS MARGIN AVG 3Y
79.37%
GROSS MARGIN AVG 5Y
81.72%
GROSS MARGIN AVG 10Y
85.20%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.08%
CURRENT VS 3Y AVG
+0.20%
CURRENT VS 5Y AVG
-2.68%
CURRENT VS 10Y AVG
-6.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+92.19%
vs the sector median at left
Market Cap
$855.35M
Gross Margin
91.39%
TTM Avg
91.47%
3Y Avg
93.85%
5Y Avg
95.64%
Market Cap
$851.60M
Gross Margin
44.60%
TTM Avg
46.45%
3Y Avg
50.53%
5Y Avg
59.76%
Market Cap
$846.39M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
Market Cap
$869.18M
Gross Margin
35.27%
TTM Avg
46.37%
3Y Avg
58.90%
5Y Avg
58.90%
Market Cap
$840.51M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$830.99M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$880.01M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $853.72M | 79.53% | 79.59% | 79.37% | 81.72% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $855.35M | 91.39% | 91.47% | 93.85% | 95.64% |
| QuidelOrtho Corporation (QDEL)vs › | $851.60M | 44.60% | 46.45% | 50.53% | 59.76% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $846.39M | 35.97% | 27.94% | 30.11% | 34.47% |
| SL Science Holding Ltd (SLBT)vs › | $869.18M | 35.27% | 46.37% | 58.90% | 58.90% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $840.51M | 0.00% | 0.00% | 0.00% | 0.00% |
| Beta Bionics, Inc. (BBNX)vs › | $830.99M | 58.31% | 55.25% | 65.77% | 65.77% |
| Alumis Inc. (ALMS)vs › | $831.93M | 88.23% | 42.73% | 21.36% | 21.36% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $880.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $876.57M | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
79.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 79.54% |
| 2026-03-31 | 79.76% |
| 2025-12-31 | 79.03% |
| 2025-09-30 | 79.84% |
| 2025-06-30 | 79.80% |
| 2025-03-31 | 79.71% |
| 2024-12-31 | 79.13% |
| 2024-09-30 | 79.09% |
| 2024-06-30 | 79.00% |
| 2024-03-31 | 78.87% |
| 2023-12-31 | 73.80% |
| 2023-09-30 | 79.30% |
| 2023-06-30 | 81.03% |
| 2023-03-31 | 81.89% |
| 2022-12-31 | 84.07% |
| 2022-09-30 | 84.23% |
| 2022-06-30 | 86.46% |
| 2022-03-31 | 86.71% |
| 2021-12-31 | 86.62% |
| 2021-09-30 | 88.88% |
| 2021-06-30 | 89.30% |
| 2021-03-31 | 89.24% |
| 2020-12-31 | 89.73% |
| 2020-09-30 | 87.35% |
| 2020-06-30 | 84.93% |
| 2020-03-31 | 88.51% |
| 2019-12-31 | 89.67% |
| 2019-09-30 | 89.93% |
| 2019-06-30 | 90.27% |
| 2019-03-31 | 89.82% |
| 2018-12-31 | 91.15% |
| 2018-09-30 | 90.88% |
| 2018-06-30 | 91.35% |
| 2018-03-31 | 91.76% |
| 2017-12-31 | 91.15% |
| 2017-09-30 | 88.63% |
| 2017-06-30 | 89.81% |
| 2017-03-31 | 87.45% |
| 2016-03-31 | 87.98% |
| 2015-03-31 | 82.84% |
| 2014-12-31 | 78.66% |
| 2014-03-31 | 88.55% |
